| 14th week of 2016 patent applcation highlights part 6 |
| Patent application number | Title | Published |
|---|
| 20160095775 | SUPPORT APPARATUS, SYSTEM AND METHOD - A therapeutic support device includes a bladder having one or more independently inflatable compartments, each including a plurality of inflatable cells. When inflated, each inflatable cell forms a contact node that may support a user or another object disposed thereon. The inflatable compartments can be alternately inflated and deflated such that contact pressure can be applied to and relieved from corresponding portions of the user's body in an alternating manner. | 2016-04-07 |
| 20160095776 | Leg Support Device - A leg elevating device is provided that is formed from foam, an air bladder, or supportive sheets of material with straps or supports. The device elevates a user's legs when laying down such that the device has a front, a back, a first side and a second side. The device has a bottom surface having and a top surface located above the bottom surface, the top surface extending upward from a front edge, and two side edges toward to form a curved shaped. The one or more apexes are located above a back edge or above a middle of the bottom surface. The top surface ends at the back of the support material at a top surface back edge. Depending on the configuration a back surface connects to the back edge of the bottom surface, and extends upward to connect to the back of the top surface. | 2016-04-07 |
| 20160095777 | Patient Transport Device with Strap Concealment Apparatus and Corresponding Methods - A patient transport device includes an inflatable torso support and one or more straps coupled to sides of the inflatable torso support. Each strap can be configured at least as a single loop. A strap concealment device can be coupled to the inflatable torso support to span a major face of the inflatable torso support. The strap concealment device can include a central panel spanning the major face and one or more side panels extending from a perimeter of the central panel. The one or more side panels can terminate at an edge distally disposed from the central panel at a bunch-gathering binding. The one or more side panels can be selectively foldable between a first position concealing the inflatable torso support and some or all of the one or more straps and a second position exposing the inflatable torso support and the one or more straps. | 2016-04-07 |
| 20160095778 | Infant Support Device - An infant holding device, including an infant holding portion, including a ductile sheet covered with infant-compatible material and a stand portion, adapted to support the infant holding portion in a vertically diagonal position, so that the infant holding portion thereby has a top and a bottom. In one preferred embodiment the ductile sheet is made of aluminum. In an additional preferred embodiment the infant holding portion is separable from the stand portion. | 2016-04-07 |
| 20160095779 | Medical Trolley Cart - A medical trolley cart having a main housing with an interior chamber. The main housing has front, back, first side, second side, top and bottom panels. A front door on the front of said main housing provides accessing an interior chamber, which may have a plurality of sliding shelves. A rear door on the rear of said main housing provides access to a rear portion of the interior chamber or to a second chamber within the cart. The rear door has a hinge around which the door is opened and a latch for holding the rear door in a closed position. The rear door opens to a maximum point at which the rear door forms an angle of 15-40 degrees with the main housing. | 2016-04-07 |
| 20160095780 | PNEUMATIC JOINT SEPARATOR FOR LOWER BODY ALIGNMENT - A leg muscle, abdominal muscle, and spinal exercise device adapted for imparting curvature to a lumbar or sacral spine of a user and for manipulating the spine and intervertebral discs with decompression force includes a frame for placement on a floor. The frame has a top surface and a bottom surface, wherein the top surface and bottom surface are in a spaced apart relationship forming a hollow portion there between. At least one inflatable bladder is carried by the top surface of the frame. A body strap attachment passes through the frame in non-fixed relationship and is partially disposed within the hollow portion for encompassing the user's thoracic-sacral spinal region and securing said frame. An elongate stirrup strap member is attachable to the body strap attachment thereby connecting to the user's spinal region. A stirrup is attachable to the stirrup strap member distal end. | 2016-04-07 |
| 20160095781 | TISSUE MASSAGE DEVICE AND METHOD - In one embodiment of the tissue massage devices and methods described herein, a tissue massage device can include a base configured to be grasped in a user's hand such that a first surface at a proximal end of the device abuts against the user's palm. The device can also include a massage head extending from a second surface of the base that is distal to the first surface, the massage head having a generally convex shape and including a textured non-slip surface formed on a distal portion thereof. The textured non-slip surface can prevent sliding motion between the device and a user's skin, thereby causing sliding between subcutaneous fascia and muscle that is therapeutic. | 2016-04-07 |
| 20160095782 | SELF-CONTAINED PORTABLE POSITIONABLE OSCILLATING MOTOR ARRAY INCLUDING DISPOSABLE AND/OR RECYCLABLE PORTIONS - In some embodiments, a system and/or method may include an inner wearable harness worn, during use, on a torso of a subject which includes a flexible vest. The system may include a plurality of engines, each of which are contained in a flexible container, which when activated apply an oscillation force. The system may include a positioning system which allows positioning the flexible container such that the oscillation force is applied to at least one treatment area of the subject. The oscillation force may mobilize, during use, at least some secretions in an airway within the subject substantially adjacent the treatment area. The system may include an outer harness worn, during use, on a torso of a subject. The outer wearable harness, when activated, adjusts the oscillation force applied by at least some of the activated plurality of engines to the treatment area by providing a compressive force. | 2016-04-07 |
| 20160095783 | SELF-CONTAINED PORTABLE POSITIONABLE OSCILLATING MOTOR ARRAY INCLUDING AN OUTER HARNESS PROVIDING A COMPRESSIVE FORCE - In some embodiments, a system may include a first wearable harness worn, during use, on a torso of a subject. The system may include a second wearable harness worn, during use, on a torso of a subject on an outer surface of the first wearable harness. The system may include a plurality of engines which when activated apply an oscillation force to at least one treatment area. At least one of the plurality of engines may be releasably couplable to the first wearable harness using a positioning system such that the oscillation force is applied to the treatment areas. The oscillation force may mobilize, during use, at least some secretions in an airway within the subject at least adjacent the treatment area. The second wearable harness, when activated, may provide a compressive force to at least some of the activated plurality of engines positioned above the treatment area. | 2016-04-07 |
| 20160095784 | STERILE LIMB CONNECTORS AND METHODS - A sterile hand connection device is used to attach a patient's arm to a cable adaptor of a surgical arm positioning apparatus. The cable adaptor is connected to two cable ends of a cable of the surgical arm positioning apparatus. The hand connection includes a clip, a buckle, and a wrap that is mounted to the clip. The buckle is attached to the cable adaptor and the clip snaps onto the buckle. The hand wrap is mounted to the clip and wraps around a patient's hand, wrist, and forearm. | 2016-04-07 |
| 20160095785 | SURGICAL ARM POSITIONING SYSTEMS AND METHODS - A surgical arm positioning system has a cable including two end portions coupled to a connection member of a hand grip. The cable and connection member form a continuous loop. The surgical arm positioning system further includes a frame that supports a number of pulleys. The continuous loop is trained around the pulleys. The surgical arm positioning system also includes a tensile resistance member engaged with the cable. The tensile resistance member provides tensile force to the cable to resist movement of the continuous loop relative to the frame, thereby to hold the patient's arm relatively still during surgery. | 2016-04-07 |
| 20160095787 | Compression Therapy Device Having Mechanical Advantage - A compression therapy device for vascular diseases and other therapies comprising a bladder a lever arm acting on the outer surface of the bladder such that cyclical operation of an actuator on the lever arm creates cyclical changes in pneumatic pressure in the therapeutic portion of the bladder. | 2016-04-07 |
| 20160095789 | Devices and Methods for Treatment and Promotion of Healing of Injured Sites - Disclosed herein is a device comprising a casing; at least one vibratory source; at least one power source; elements to actuate the vibratory source; electrical communication between the vibratory source, the power source, and other elements; and an optional thermal element for modulating the temperature of a contacted area of a surface. Also disclosed herein are methods for using the device. | 2016-04-07 |
| 20160095793 | METHOD OF CLEARING A BIOLOGICAL AIRWAY USING A SELF-CONTAINED PORTABLE POSITIONABLE OSCILLATING MOTOR ARRAY - In some embodiments, a method may include clearing a biological airway. The method may include positioning an inner wearable harness on a torso of a subject. The method may include selectively positioning at least some of a plurality of engines on and/or adjacent at least one treatment area. At least one of the plurality of engines may be releasably couplable to the inner wearable harness. The method may include positioning an outer wearable harness on a torso of a subject. The method may include applying an oscillation force to at least one of the treatment areas using at least some of the plurality of engines. The method may include adjusting the applied oscillation force to the treatment area by activating the outer wearable harness. The method may include mobilizing at least some secretions in an airway within the subject substantially adjacent the at least one treatment area. | 2016-04-07 |
| 20160095794 | FLUSHING SYSTEM FOR A SAFETY SYSTEM - Methods and apparatus for improving emergency wash systems. Various embodiments pertain to compact, low flow emergency eyewash systems that provide tepid water at low flow rates. Still further embodiments pertain to emergency washing systems that are adapted and configured to reduce the exposure of users to Legionnaire's Disease with washing system features that permit quick, efficient, high flow rate flushing of the plumbing providing water to the washing system. Still further embodiments pertain to emergency eyewash systems that provide tepid water from a thermostatically controlled mixing valve that has a multi-function body. | 2016-04-07 |
| 20160095795 | DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LEVEMIR, NOVOLOG, NOVOLIN 70-30, NOVOLIN R, NOVOLIN N, NOVOLOG MIX 70-30 and NOVOLIN L. | 2016-04-07 |
| 20160095796 | DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PROCRIT (epoetin alfa), REMICADE (Infliximab) or DORIBAX (doripenem). | 2016-04-07 |
| 20160095797 | Medication Dispensing Assembly - A medication dispensing assembly includes a canister that has an outer wall extending between a top end and a bottom end of the canister. The top end of the canister is open so the canisters may contain a medication. A lid is coupled to the top end of the canister. A processor is coupled to the canister. A timer is coupled to the canister and the processor. The timer determines a trigger time that the medication is to be removed from the canister. An actuator is coupled to the canister and the processor. The actuator is actuated to determine the trigger time. An alarm is coupled to the canister and the processor. A sensor is coupled to the canister and the processor. The alarm continuously emits an audible alarm until the sensor detects that the lid is positioned in the open position. | 2016-04-07 |
| 20160095798 | NANOCRYSTALLINE ZIRCONIA AND METHODS OF PROCESSING THEREOF - Zirconia dental ceramics exhibiting opalescence and having a grain size in the range of 10 nm to 300 nm, a density of at least 99.5% of theoretical density, a visible light transmittance at or higher than 45% at 560 nm, and a strength of at least 800 MPa. | 2016-04-07 |
| 20160095799 | METHOD FOR MAKING A MACHINABLE BLOCK OF POLYURETHANE ELASTOMER FOR USE IN FABRICATING DENTAL APPLIANCES - A method of making a machinable puck of a hard, solvent free, substantially non-hydrophilic polyurethane elastomer for use in fabricating dental appliances. The elastomer has a hardness of not less than about Shore D65. A first polyester or polyether polyol with a functionality greater than two and a molecular weight greater than one hundred is reacted with an isocyanate prepolymer prepared from one or more branched polyester or polyether polyols with a functionality greater than two; and then blending prepolymer and first polyester or polyether polyol with nanoparticles and colorants as needed. In one embodiment, the polypropylene glycol triether and the isocyanate prepolymer comprises dicyclohexylmethane 4,4′-diisocyanate. The machined, elastomer appliance is able to be heated in hot water to make it flexible and formable for individual, customed-fitting for the patient. | 2016-04-07 |
| 20160095800 | POLYURETHANE ELASTOMER DENTAL APPLIANCE - A dental jacket made of a hard, solvent free, substantially non-hydrophilic polyurethane elastomer. The jacket elastomer has a hardness of not less than about Shore D65. A polyester or polyether polyol with a functionality greater than two and a molecular weight greater than one hundred is reacted with an isocyanate prepolymer prepared from one or more branched polyester or polyether polyols with a functionality greater than two; and then blending prepolymer and first polyester or polyether polyol with nanoparticles. In one embodiment, the polypropylene glycol triether and the isocyanate prepolymer comprises dicyclohexylmethane 4,4′-diisocyanate. | 2016-04-07 |
| 20160095801 | MULTI-COMPONENT DENTAL WHITENING COMPOSITIONS - A two-component tooth whitening system containing a bleaching gel and an activating gel, including that the system has both thermo- and foaming-stability for non-refrigerated storage. The admixing of the two components provides effective whitening and proper bubbling that enables oxygen and free radicals released to diffuse into tooth enamel, and thus, provides significant whitening efficacy. | 2016-04-07 |
| 20160095802 | COMBINATION OF PETROSELINIC ACID AND ZINC FOR ORAL ADMINISTRATION FOR HAIR AGING CONTROL - The invention relates to the cosmetic use, by oral administration, of a combination of active agents including petroselinic acid and zinc, in particular the salts of Zn (II) wherein said salts are preferably complexed by one or more (poly)hydroxyacids such as zinc gluconate, for improving hair quality and for preventing and controlling the microinflammation of hair follicles, in particular for controlling hair aging in men over the age of 30 or in women. | 2016-04-07 |
| 20160095803 | COMBINATION OF ACTIVE AGENTS FOR ORAL ADMINISTRATION FOR IMPROVING THE QUALITY OF NAILS - The invention relates to the cosmetic use, by oral administration, of a combination of active agents including at least petroselinic acid and at least one active agent selected from among taurine, arginine, cysteine, zinc, a salt thereof, and lycopene, for improving the quality of nails, specifically the microvascularization of the nails, in particular in pre-hypertensive individuals. | 2016-04-07 |
| 20160095804 | SULFATE-FREE CLEANSING COMPOSITION WITH THICKENER - Disclosed is an aqueous cleansing composition comprising (a) at least one anionic surfactant that is not an alkyl sulfate or alkyl ether sulfate, (b) at least one amphoteric surfactant, (c) at least one thickener selected from a hydrophobically-modified acrylic acid based copolymer having a molecular weight from about 80,000 to about 2,500,000 grams per mole, (d) at least one cationic conditioning agent, and (e) optionally at least one nonionic surfactant; wherein the ratio of the anionic surfactant (a) to amphoteric surfactant (b) is less than about 9.5, by weight. Also disclosed are methods of cleaning and conditioning hair using said compositions and methods of making said compositions. | 2016-04-07 |
| 20160095805 | Cation Compatible Metal Oxides and Oral Care Compositions Containing the Metal Oxides - A cationic compatible metal oxide and oral care compositions containing the metal oxide are disclosed. Preferably, the oral care compositions contain a cationic compatible metal oxide and a cationic ingredient, such as for example, a cationic antibacterial agent such as cetyl pyridinium chloride (“CPC”). The cationic compatible metal oxide, e.g. silica, comprise metal oxide particles having a subtantially negative surface charge and a vitamin deposited onto or reacted with the surface of the metal oxide particles in an amount sufficient to provide a substantially positive surface charge on the metal oxide particle. Processes for making and using the vitamin modified metal oxide in oral care compositions are also disclosed. | 2016-04-07 |
| 20160095806 | Allantoin-Containing Skin Cream - An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composite can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component or a preservative component. The composition is useful as a skin protectant. | 2016-04-07 |
| 20160095807 | METHOD OF ACHIEVING IMPROVED VOLUME AND COMBABILITY USING AN ANTI-DANDRUFF PERSONAL CARE COMPOSITION COMPRISING A PRE-EMULSIFIED FORMULATION - The present invention is directed to a method of achieving improved hair volume comprising applying to hair a composition comprising from about 0.25% to about 80% of a pre-emulsified emulsion comprising from about 0.005% to about 80% of one or more materials selected from the group comprising metathesized unsaturated polyol esters, sucrose polyesters, fatty esters with a molecular weight greater than or equal to 1500 and mixtures thereof or, by weight of said hair care composition; wherein an emulsifier is selected from the group consisting of anionic, non-ionic, cationic, amphoteric and mixtures thereof wherein the average particle size of the pre-emulsified emulsion is from about 20 nanometers to 20 microns; from about 5% to about 50% of one or more anionic surfactants, by weight of said hair care composition; from about 0.01% to about 5% of an anti-dandruff active; at least about 20% of an aqueous carrier, by weight of said hair care composition wherein the method provides to the hair a dry static friction index of about 1.05-3 and a dry combing index of about greater than or equal to about 1.05. | 2016-04-07 |
| 20160095808 | HAIR CARE COMPOSITION COMPRISING DISCRETE PARTICLE OF OILY COMPONENT - Disclosed is a hair care composition comprising: a discrete particle comprising an oily component, wherein the oily component comprises one or more materials selected from the group consisting of: (A) metathesized unsaturated polyol esters; (B) sucrose polyesters; (C) fatty esters with a molecular weight greater than or equal to 1500; and mixtures thereof, wherein the oily component has a Zero Shear Viscosity at 25° C. of from about 10 | 2016-04-07 |
| 20160095809 | METHOD OF IMPROVED VOLUME AND COMBABILITY USING PERSONAL CARE COMPOSITION COMPRISING A PRE-EMULSIFIED FORMULATION - In an embodiment, the present invention is directed a method of achieving hair volume and combability comprising applying to hair a personal care composition comprising from about 0.25% to about 80% of a pre-emulsified emulsion comprising from about 0.005% to about 80% of one or more materials selected from the group comprising metathesized unsaturated polyol esters, sucrose polyesters, fatty esters with a molecular weight greater than or equal to 1500 and mixtures thereof or, by weight of said hair care composition; wherein an emulsifier is selected from the group consisting of anionic, non-ionic, cationic, amphoteric and mixtures thereof wherein the average particle size of the pre-emulsified emulsion is from about 20 nanometers to 20 microns; from about 5% to about 50% of one or more anionic surfactants, by weight of said hair care composition; from about 5% to about 40% of a gel matrix comprising:
| 2016-04-07 |
| 20160095810 | Cosmetic and/or dermatological compositions containing polyphenols stabilized by perfluoropolyether phosphates and use of perfluoropolyether phosphates as stabilizing agents for polyphenols - The present invention concerns the use of perfluoropolyether phosphates, in particular perfluoropolyether diphosphates, as stabilizing agents for polyphenols in cosmetic and/or dermatological compositions for topical application, and it also concerns cosmetic and/or dermatological compositions containing polyphenols and optionally vitamin E and free ascorbic acid, stabilized by perfluoropolyether diphosphates. | 2016-04-07 |
| 20160095811 | METHODS OF TREATING AND/OR PREVENTING NAIL DISORDERS AND/OR IMPROVING THE APPEARANCE OF A NAIL - Systems and/or methods of treating and/or preventing nail disorders are disclosed herein. Also, disclosed herein are systems and/or methods of improving the appearance of a nail. A preferred embodiment of the present invention comprises a method of treating and/or preventing a nail disorder in a subject comprising topically applying a composition comprising a poly(urea-urethane)polymer and/or a poly(urea-urethane) pre-polymer to a nail of said subject, thereby treating and/or preventing said nail disorder. | 2016-04-07 |
| 20160095812 | ESSENTIAL OIL OF SATUREJA MONTANA WITH A HIGH GERANIOL CONTENT, AND USE FOR TREATING GREASY SKIN AND/OR THE ASSOCIATED AESTHETIC DEFECTS - The present invention relates to an essential oil of | 2016-04-07 |
| 20160095813 | TOPICAL FACIAL MASK COMPOSITION FOR SKIN CARE - In certain embodiments, the invention is directed to a formulation for providing skin tightening which includes two or more of the following agents: red split lentils, Multani Mitti, charoli, chandan powder, and turmeric powder. Two or more of the agents can be ground and combined together in an effective amount. The combined agents can be additionally combined with a topical excipient. | 2016-04-07 |
| 20160095814 | COSMETIC COMPOSITIONS - Disclosed are compositions and methods for their use that can be used in cosmetic applications. The composition can include an effective amount of a | 2016-04-07 |
| 20160095815 | SUBSTANCE FOR RESTORING NORMAL CO-EXPRESSION AND INTERACTION BETWEEN THE LOX AND NRAGE PROTEINS - The invention relates to the use of a substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins. The invention relates in particular to the use of an effective amount of at least one substance that modulates the expression and/or activity of the LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of the NRAGE of SEQ ID NO: 2 for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible to treat skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type. | 2016-04-07 |
| 20160095816 | ARTICLE AND METHODS FOR ORAL SELF-ADMINISTRATION OF NICOTINE - The invention discloses an article for swaddling in the mouth to deliver pharmacologically active substances, particularly nicotine, in combination with dyes or flavorings, across the buccal membranes when said article is swaddled in the mouth. The article comprises a non-edible substantially cylindrical core element, such as a toothpick, and the indicator element may be a bulb, trinket, insignia or other marking. In a preferred embodiment, the invention makes a social statement about the beneficial uses of nicotine. Methods for using the invention to mitigate sensations of nervousness and boredom are also disclosed. | 2016-04-07 |
| 20160095817 | Liposomes Useful for Drug Delivery - The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. | 2016-04-07 |
| 20160095818 | SOLID PHARMACEUTICAL DOSAGE FORM FOR RELEASE OF AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT IN THE ORAL CAVITY - Solid pharmaceutical dosage form for the release of at least one Active Pharmaceutical Ingredient (API) in the oral cavity comprising a core coated by at least one film coating. The core comprises at least one API. One or more organoleptically disturbing sensations induced by one or several of the APIs and/or of inactive components of the solid pharmaceutical dosage form is/are reduced by constituents of said film coating. Said constituents comprise at least one film-forming polymer and at least one flavoring agent or at least one sweetener. | 2016-04-07 |
| 20160095819 | Pharmaceutical compositions containing flibanserin - The invention relates to oral pharmaceutical compositions containing flibanserin, methods for the preparation thereof and use thereof as a medicament. | 2016-04-07 |
| 20160095820 | METHOD AND PROCESS FOR THE PRODUCTION OF MULTI-COATED RECOGNITIVE AND RELEASING SYSTEMS - The present invention includes compositions, methods, systems and kits for the controlled delivery of an active agent within a polymeric network upon the binding of a molecule that decreases the structural integrity of the polymeric network at one or more micro- or nanovacuoles. | 2016-04-07 |
| 20160095821 | ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE - The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized. | 2016-04-07 |
| 20160095822 | Multiparticulate L-Menthol Formulations and Related Methods - A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core. | 2016-04-07 |
| 20160095823 | METHODS OF USING PROPOFOL DERIVATIVES FOR ANALGESIA - The present invention concerns compounds derived from the anaesthetic propofol that are useful as analgesics and methods of using the same. The compounds act as co-activators of strychnine-sensitive glycine receptors and may have greater activity at those glycine receptors than at GABA | 2016-04-07 |
| 20160095824 | USE OF VITAMIN K FOR WEIGHT MAINTENANCE AND WEIGHT CONTROL - Vitamin K is effective in counteracting (1) increase of body weight and body mass index (BMI), (2) accumulation of body fat mass and (3) accelerates weight loss during calory restriction or other life style interventions aiming weight reduction. A pharmaceutical composition or nutritional formulation comprising vitamin K is provided which can be used to combat overweight or obesity, either as a single, dedicated product or in combination with other slimming products or life style changes. | 2016-04-07 |
| 20160095825 | ANIMAL TREATMENTS - Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal. | 2016-04-07 |
| 20160095826 | METHODS OF DIAGNOSIS AND TREATMENT - A method for diagnosing a cardiac ischemic event and a kit for detecting biomarkers used in the method. Also provided is a method for treating a PPAR-related disorder by administering a pharmaceutical composition containing one or more long chain fatty acids. | 2016-04-07 |
| 20160095827 | DELAYED RELEASE CYSTEAMINE BEAD FORMULATION, AND METHODS OF MAKING AND USING SAME - An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed. | 2016-04-07 |
| 20160095828 | Compositions and Methods for Treating Metabolic Disorders - Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine. | 2016-04-07 |
| 20160095829 | TRPV1 COMPOUNDS IN A BIODEGRADABLE POLYMER CARRIER - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of a TRPV1 compound (e.g., capsaicinoid compound) at or near a target site, one can relieve pain caused by diverse sources, including but not limited to, postoperative pain, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 2016-04-07 |
| 20160095830 | CO-ADMINISTRATION OF INTRAVENOUS IBUPROFEN AND ACETAMINOPHEN FOR TREATMENT OF PAIN - An effective dose of intravenous ibuprofen administered co-adminstered with intravenous acetaminophen in surgery patients is a safe and effective way to reduce both pain and the need for opioid analgesics. In preferred embodiments, the administration of intravenous ibuprofen and intravenous acetaminophen starts no later than at approximately the completion of wound closure. | 2016-04-07 |
| 20160095831 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY - In certain aspects the methods comprise administering an inhibitor of hydrogen sulfide biosynthesis, a cystathionine-β-synthase (CBS) inhibitor, or a hydrogen sulfide neutralizing agent to a patient having a cancer associated with elevated production of hydrogen sulfide. | 2016-04-07 |
| 20160095832 | TOPICAL COMPOSITION FOR PAIN RELIEF - The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic. | 2016-04-07 |
| 20160095833 | BRANCHED CHAIN FATTY ACIDS FOR PREVENTION OR TREATMENT OF GASTROINTESTINAL DISORDERS - The present invention is directed to a method of preventing or treating a gastrointestinal condition in a subject, that includes administering one or more branched chain fatty acid to the subject under conditions effective to prevent or treat the gastrointestinal condition in the subject. The present invention is also directed to methods of promoting gastrointestinal health in a subject and propagation of probiotic organisms. Also disclosed is a formulation which includes one or more branched chain fatty acid and an aqueous phase emulsified with the one or more branched chain fatty acids, where the formulation includes over 25 wt % of the one or more branched chain fatty acid. | 2016-04-07 |
| 20160095834 | FOOD AND DRINK - The present invention provides a food or drink that emits no offensive odor typified by a fish odor in any form of the food or drink, such as liquid, gel, semi-solid, or solid form, and also suppresses emission of an offensive odor due to time-dependent changes. Further, a food or drink is provided that has, particularly, a superior action of inhibiting platelet aggregation to that of conventional fish-derived EPA and DHA-containing food. The food or drink comprise an algae extract oil, an animal or plant protein, and an emulsifier. | 2016-04-07 |
| 20160095835 | COMPOSITIONS CONTAINING OMEGA-3 OIL AND USES THEREOF - The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules. The invention further provides kits containing these pharmaceutical compositions, methods for formulating pharmaceutical compositions containing omega-3 oil, and methods for decreasing the likelihood of developing cardiovascular disease, decreasing triglyceride or LDL cholesterol levels, decreasing pain or inflammation, treating diabetes, chronic pulmonary diseases, or irritable bowel syndrome, decreasing symptoms of an autoimmune disease or allergic conditions. | 2016-04-07 |
| 20160095837 | MODULATION OF MITOCHONDRIAL CALCIUM UNIPORTER ACTIVITY FOR TREATING AND PREVENTING ARRHYTHMIAS - Disclosed are methods and compositions for treating or preventing diseases or disorders associated with mitochondrial calcium uniporter (MCU) activity. The methods may include administering a modulator of MCU activity to a patient in need thereof. | 2016-04-07 |
| 20160095838 | TARGETED POLYMERIC CONJUGATES AND USES THEREOF - Polymeric conjugates comprising a polymeric backbone having attached thereto a bone targeting moiety and a therapeutically active agent, wherein the bone targeting moiety is attached to one end of the polymeric backbone via a branching unit such that a molar ratio of the bone targeting moiety to the polymer is at least 2:1, are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed. | 2016-04-07 |
| 20160095839 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING AUTOIMMUNE CONDITIONS AND DELAYING OR PREVENTING AUTOIMMUNE RELATED PATHOLOGIC PROGRESSIONS - Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases. | 2016-04-07 |
| 20160095840 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST - Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided. | 2016-04-07 |
| 20160095841 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK - The present invention relates to a compound of formula (I): | 2016-04-07 |
| 20160095842 | COMBINATION THERAPY CONTAINING A PI3K-ALPHA INHIBITOR AND FGFR KINASE INHIBITOR FOR TREATING CANCER - A pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof and a fibroblast growth factor receptor (FGFR) kinase inhibitor, particularly for simultaneous, separate or sequential use for the treatment of a cancer; use of such pharmaceutical combination for the preparation of a medicament for the treatment of a cancer; use of such pharmaceutical combination for the treatment a cancer; a method for treating a cancer comprising administering to a subject having said cancer a jointly therapeutically effective amount of such combination; and related pharmaceutical compositions or kits thereof. | 2016-04-07 |
| 20160095843 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 2016-04-07 |
| 20160095844 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES - The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula | 2016-04-07 |
| 20160095845 | COMPOSITION COMPRISING (S)-(-)-BENPROPERINE FOR PREVENTING OR TREATING CANCER - The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising (S)-(−)-benproperine or a pharmaceutically acceptable salt thereof as an active ingredient, and a method for preventing or treating cancer using the same. | 2016-04-07 |
| 20160095846 | SUBLINGUAL FENTANYL SPRAY - The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable sale thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations. | 2016-04-07 |
| 20160095847 | DEUTERATED ANALOGS OF PRIDOPIDINE USEFUL AS DOPAMINERGIC STABILIZERS - The present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine. Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease. | 2016-04-07 |
| 20160095848 | PHENYLPYRROLE DERIVATIVE - Provided are novel compounds that are useful in the prevention or treatment of such diseases as dementia, Alzheimer's disease, attention-deficient hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, and depression, or allergic rhinitis, or pharmaceutically acceptable salts of such compounds. Specifically, there are provided phenylpyrrole compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: | 2016-04-07 |
| 20160095849 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND - The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT | 2016-04-07 |
| 20160095850 | METHODS AND COMPOSITIONS FOR TREATMENT OF HIV INFECTION - Methods and compositions for treatment of human immunodeficiency virus (HIV) infections have been developed which dampen immune activation with a bias more on the CD4 T cells relative to the CD8 T cell response, inhibit HIV replication, reactivate latent HIV, and inhibit infection of cells by HIV. Pushing latent HIV into active infections with hindrance of cell infection by the reactivated HIV can substantially reduce the number of cells infected with HIV and the viral load of HIV, which is not achieved using just the combination of ART and compounds which activate latent HIV. The methods involve administering to an HIV-infected subject three or more compounds which collectively dampen immune activation with a bias more on the CD4 T cells relative to the CD8 T cell response, inhibit HIV replication, reactivate latent HIV, and inhibiting infection of CD4 T cells by HIV. | 2016-04-07 |
| 20160095851 | SUBLINGUAL APOMORPHINE - The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith. | 2016-04-07 |
| 20160095852 | Liposomes Useful for Drug Delivery - The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. | 2016-04-07 |
| 20160095853 | USE OF BINDERS FOR MANUFACTURING STORAGE STABLE FORMULATIONS - The present invention relates to storage stable prolonged release pharmaceutical dosage forms comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof, the manufacture thereof as well as their use for administration to human beings. | 2016-04-07 |
| 20160095855 | USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE - The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments. | 2016-04-07 |
| 20160095856 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS - Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer. | 2016-04-07 |
| 20160095857 | METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF ERYTHEMA - Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier. | 2016-04-07 |
| 20160095858 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator - The present invention features a compound of formula I: | 2016-04-07 |
| 20160095859 | COMBINATION THERAPIES FOR OVERCOMING RESISTANCE TO MITOTIC AGENTS DURING CHEMOTHERAPY - This disclosure relates to the uses of compounds that target an interaction between CHFR and PARP1. In certain embodiments, the disclosure relate to treating cancer by administering a mitotic inhibitor such as a taxane and a vinca alkaloid in combination with a compound that inhibits CHFR and PARP1 interactions, such as 5-((1-benzyl-1H-indol-3-yl)methylene)-1-(3,4-dimethylphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione, derivatives or salts thereof, optionally in further combination with a third anti-cancer agent. | 2016-04-07 |
| 20160095860 | Pharmaceutical Composition Comprising Progestogens and/or Estrogens and 5-Methyl-(6S)-tetrahydrofolate - The present invention relates to a pharmaceutical composition which comprises progestogens, preferably drospirenone, estrogens, preferably ethinylestradiol and 5-methyl-(6S)-tetrahydrofolate, can be employed as oral contraceptive and moreover prevents disorders caused by folate deficiency in the consumers, in particular cardiovascular disorders and, after conception of the embryo, congenital malformations caused by folate deficiency such as, for example, neural tube defects, ventricular valve defects, urogenital defects, and cleft lip, jaw and palate, without masking the symptoms of vitamin B | 2016-04-07 |
| 20160095861 | OPHTHALMIC OINTMENTS COMPRISING VALGANCICLOVIR HYDROCHLORIDE FOR TREATING INFECTIVE EYE DISEASES - The present invention provides ophthalmic ointments for treating infective eye diseases containing valganciclovir hydrochloride as an active ingredient in the amount of from about 0.01% to about 10.0% w/w. These ophthalmic ointments are particularly effective for treating eye diseases caused by herpesviruses in the eye. Compared with oral administration, topical administration of valganciclovir hydrochloride is not accompanied by systemic side effects such as bone marrow suppression. Compared with topical administration of ganciclovir, topical administration of valganciclovir hydrochloride is much more effective in treating infective diseases in the eye and is not accompanied by toxicity to the surface of the eye. | 2016-04-07 |
| 20160095862 | Methods and Devices for Renal Nerve Blocking - Drug eluting implants for targeted delivery of a nerve-blocking agent to inhibit neural traffic along renal nerves of a human patient. | 2016-04-07 |
| 20160095863 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA and MYELODYSPLASTIC SYNDROME - The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Quizartinib or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). | 2016-04-07 |
| 20160095864 | COMPOSITION FOR REDUCING CELL SENESCENCE COMPRISING RHO-KINASE INHIBITOR AND USE THEREOF - A composition for reducing cell senescence including a Rho-kinase inhibitor and method of treating a cell senescence-related symptom in mammals. | 2016-04-07 |
| 20160095865 | APPLICATION OF ENROFLOXACIN SALT IN PREPARATION OF ORAL PREPARATION FOR PIGS - The invention discloses application of an enrofloxacin salt in preparation of an oral preparation for pigs. The enrofloxacin salt is at least one of salts formed by enrofloxacin and metal ions, and the metal ions are zinc, copper, calcium, magnesium, iron, cobalt, manganese, chromium, silver or nickel. The enrofloxacin salt formed by the enrofloxacin and the metal ions can significantly improve the palatability of the enrofloxacin to pigs; furthermore pharmacokinetics and artificial infection prove that the enrofloxacin salt formed by the enrofloxacin and the metal ions does not affect bioavailability, so enrofloxacin salt can be developed into the oral preparation administrated via the digestive tract, for pig-raising without affecting normal feed intake of the pigs. | 2016-04-07 |
| 20160095866 | 1,4-Benzodiazepone-2,5-Diones And Related Compounds With Therapeutic Properties - The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzodiazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with ROCK activity. | 2016-04-07 |
| 20160095867 | BET INHIBITION THERAPY FOR HEART DISEASE - Method for treating cardiac diseases using BET inhibitors including JQ1 are provided. Methods for treating cardiac hypertrophy, method for treating heart failure not arising from inflammation, methods for treating myocardial infarction, methods for cardioprotection and methods for inhibiting restenosis are described herein. The methods involve the use of effective amounts of BET inhibitors such as JQ1. | 2016-04-07 |
| 20160095868 | COMPOSITION, FORMULATIONS AND METHODS OF MAKING AND USING BOTANICALS AND NATURAL COMPOUNDS FOR THE PROMOTION OF HEALTHY BRAIN AGING - The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults, especially adult women, and for prevention of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction. | 2016-04-07 |
| 20160095869 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION - An exemplary embodiment relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. An exemplary embodiment provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ΔF508-CFTR, or another mutation of class II. | 2016-04-07 |
| 20160095870 | METHODS OF FORMING CYCLOPIROX OR DERIVATIVES THEREOF IN A SUBJECT BY ADMINISTRATION OF PRODRUG - A method of forming a compound in a subject can include: providing a composition having a prodrug compound represented by a structure of Formula 1 or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the composition to a subject such that the prodrug compound has a phosphoryloxyalkyl prodrug moiety removed therefrom to form the compound in the subject and to form the separate phosphoryloxyalkyl compound. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, various cancers (e.g., bladder, breast, etc.), dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, | 2016-04-07 |
| 20160095871 | Osteoclast Inhibitors for Knee Conditions - Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions. | 2016-04-07 |
| 20160095872 | Therapeutic Compositions Comprising Imidazole and Imidazolium Compounds - Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain. | 2016-04-07 |
| 20160095873 | COMPOSITIONS AND METHODS FOR TRANSIENT UP-REGULATION OF MYC IN B-CELL LYMPHOMAS FOR ENHANCING P53 INDEPENDENT APOPTOTIC RESPONSES TO CHEMOTHERAPY - Compositions and methods useful for the treatment of cancer, particularly lymphoma, are disclosed. | 2016-04-07 |
| 20160095874 | METHOD OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH FARNESYLTRANSFERASE INHIBITORS - The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients. | 2016-04-07 |
| 20160095875 | SDF-1 binding nucleic acids and the use thereof in cancer treatment - The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer. | 2016-04-07 |
| 20160095876 | COMPOSITION AND KITS FOR INHIBITION OF PATHOGENIC MICROBIAL INFECTION AND METHODS OF USING THE SAME - Antimicrobial polymer coating formulations are prepared that protect biological surfaces by treating, reducing, ameliorating, preventing or inhibiting pathogenic microorganism ingress to a human or animal host, reducing the potential for infection, particularly by necrotizing fasciitis originating microorganisms, through use of an polymer coating barrier containing antimicrobial agents that facilitates sustained release of biocidal agents active against such opportunistic microorganisms. Such formulations are effective for inhibiting microbial ingress pertaining to soft tissue and skin tears, abrasions, punctures and surgical wounds, and can be used as in water environments and as a skin protectant sunscreen and insect repellent. | 2016-04-07 |
| 20160095877 | Use of Certain Foods and Dietary Supplements as Water and Beverage Activating Enerceuticals - The Applicant has identified a biological energy pathway, which is distinct from photosynthesis and from the generation of cellular energy through normal metabolism. It is referred to as the third or the alternative cellular energy (ACE) pathway. This pathway is expressed through an energy acquired kinetic activity of water molecules. The present application extends on the breadth of compounds capable of transferring a natural force called KELEA, (kinetic energy limiting electrostatic attraction) to water and to both non-alcoholic and alcoholic beverages. They include common dietary supplements such as humic acids and common foods, such as cocoa. These products can be repeatedly used for liquid activation at very low quantities and can be removed from the liquid prior to the liquid being used for biological purposes. The studies have widespread practical applications in human and animal health as well as in agriculture. The studies also provide for a better understanding of the practice of homeopathy. | 2016-04-07 |
| 20160095878 | PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME - The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels. | 2016-04-07 |
| 20160095879 | COMPOSITION FOR ENHANCING IMMUNITY - The invention relates to preparations for dietary, food supplement or medical purposes and more specifically to a safe and natural preparation or a composition useful in immunity regulation and/or stimulation and in particular in the building, reinforcement, efficiency, maintenance and regeneration of natural immune defences in a subject. The preparations comprise magnesium, zinc and/or iron, blackcurrent seed oil and/or palm oil, two plant extracts selected from thyme, chickpea and lentil, as well as algae (fucus, wakame, nori), mushroom (shiitake, maitake) and at least one hydrosoluble vitamin and/or vitamin E. | 2016-04-07 |
| 20160095880 | HYDROXYAPATITE TISSUE FILLER AND ITS PREPARATION AND USE - The invention pertains to a biocompatible composition, suitable for use in soft or hard tissue augmentation, wherein the composition is an aqueous suspension containing a carrier fraction of ceramic particles of less than 15 μm and an augmentation fraction of ceramic particles of at least 20 μm. The ceramics typically comprise calcium phosphate. The composition is a may be used in soft tissue repair as well as hard bone replacement. It advantageously avoids the need for foreign body materials which are conventionally applied to stabilize augmentation suspensions. | 2016-04-07 |
| 20160095881 | Promoting Muscle Building and Repair and Treating Disorders Related to Collagen and Pertinent Proteins by Using Shilajit - A method of using Shilajit or its individual components, or a combination of two or more of these components, to induce the body of a mammal, including that of a human, to synthesize new collagen and the related extracellular matrix proteins, thus promoting the health of all of the tissues and organs containing collagen and the related extracellular matrix proteins, including skin, connective tissue, muscle, cartilage, bone, and teeth and improve muscle building and regeneration, and/or treat collagen-related disorders is presented. | 2016-04-07 |
